Emergent BioSolutions | EBS - Market Capitalization


Emergent BioSolutions reported $424.4M in Market Capitalization this March of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
Akebia Therapeutics USD 502M 75M Mar/2025
ALKERMES USD 4.62B 333M Dec/2025
Alnylam Pharmaceuticals USD 52.54B 7.24B Dec/2025
Amarin USD 341M 4M Sep/2025
ANI Pharmaceuticals USD 1.77B 269M Dec/2025
BioMarin Pharmaceutical USD 11.76B 348M Mar/2026
Coherus Biosciences USD 94M 65M Mar/2025
Emergent BioSolutions USD 125M 51M Dec/2023
Exelixis USD 11.75B 959M Dec/2025
Glaxosmithkline GBP 86.88B 7.29B Sep/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
Lonza CHF 39.68B 980.61M Jun/2025
Merck USD 261.26B 51.62B Dec/2025
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Pacira USD 1.06B 94M Dec/2025
Pfizer USD 141.57B 6.48B Dec/2025
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Sanofi EUR 100.88B 4.46B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
United Therapeutics USD 20.98B 2.02B Dec/2025
Vanda Pharmaceuticals USD 279M 6M Dec/2024